IL6 and COVID-19: The authors of this study suggest a clinical trial exploring a specific blocker of the IL‐6 pathway such as tocilizumab to restore the expression of HLA‐DR, and to alleviate the immune‐paralysis seen in severe COVID‐19 cases.